REGN668

BIOLOGICAL2 trials

Sponsors

Regeneron Pharmaceuticals

Conditions

DermatitisHealthy

Phase 1

Ascending Dose Study of the Safety and Tolerability of REGN668(SAR231893) in Normal Healthy Volunteers

CompletedNCT01015027

Regeneron PharmaceuticalsHealthy

Start: 2009-10-31End: 2010-07-31Updated: 2013-06-17

Sequential Ascending Dose Study to Assess the Safety and Tolerability of REGN668 (SAR231893) in Patients With Atopic Dermatitis

CompletedNCT01259323

Regeneron PharmaceuticalsDermatitis

Start: 2010-12-31End: 2012-07-31Updated: 2012-10-04

Related Papers

Dupilumab Provides Favorable Safety and Sustained Efficacy for up to 3 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis

American Journal of Clinical Dermatology2020-06-17128 citations

Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis

New England Journal of Medicine2014-07-091382 citations